Novo Nordisk
NYSE:NVO Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 226 Fair Values set on narratives written by author
BE
Bejgal
Community Contributor
Novo Nordisk will dominate GLP-1 market with Ozempic and Wegovy growth
Catalysts ◦ Strong position in the GLP-1 drug market , leading with Ozempic for diabetes and Wegovy for obesity. These products have driven significant growth.
View narrativeUS$85.93
FV
11.7% undervalued intrinsic discount18.85%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
5 days ago author updated this narrative